Ifosfamide Baxter Healthcare (Ifosfamide)

Ifosfamide is employed in oncology as a DNA‑alkylating agent for several tumour types.

• Testicular cancer: used in combination regimens to achieve tumour shrinkage and improve survival.
• Soft tissue sarcoma: incorporated into multi‑drug protocols to control disease progression.
• Ovarian cancer: administered as part of salvage chemotherapy for resistant disease.
• Lymphoma: utilized in refractory cases to induce remission.
• Wilms tumor: given in pediatric protocols to enhance cure rates.
• Neuroblastoma: applied in high‑risk treatment schedules to reduce tumour burden.

• Ifosfamide is a nitrogen‑mustard alkylating agent that forms covalent bonds with DNA bases, leading to intra‑ and interstrand cross‑links. These cross‑links obstruct DNA replication and transcription, triggering cell‑cycle arrest and apoptosis in rapidly dividing cancer cells. The drug is activated intracellularly by hepatic cytochrome P450 enzymes to its cytotoxic metabolites.

Ifosfamide may cause a range of adverse reactions, which are monitored during therapy.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during treatment.
• Myelosuppression: reduced white blood cells, red cells and platelets.
• Fatigue: generalized tiredness often reported by patients.
• Alopecia: temporary hair loss during cycles.

Serious or Rare Side Effects

• Hemorrhagic cystitis: bladder irritation that may cause bleeding.
• Neurotoxicity: confusion, seizures or encephalopathy in severe cases.
• Nephrotoxicity: impaired kidney function requiring monitoring.

When using Ifosfamide, clinicians should observe several safety measures.

• Hydration: ensure adequate intravenous fluids to reduce risk of bladder toxicity.
• Mesna co‑administration: provide uroprotective agent to prevent hemorrhagic cystitis.
• Renal function monitoring: assess serum creatinine and electrolytes before each dose.
• Neurological assessment: watch for signs of encephalopathy or seizures.
• Pregnancy category D: avoid use in pregnant women unless benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Ifosfamide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase toxic metabolite levels.
• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): heighten risk of kidney injury.

Moderate Interactions (Monitor Closely)

• CYP inducers (e.g., rifampin, phenytoin): may reduce therapeutic effect.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding risk.
• Other myelosuppressive drugs: increase likelihood of severe bone‑marrow suppression.